Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin

Experimental Eye Research

Volumn 84, Issue 3, 2007, Pages 569-576

  Kohno, Hideo ^a   Sakai, Tsutomu ^a   Saito, Saburo ^a   Okano, Kiichiro ^a   Kitahara, Kenji ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

atorvastatin; experimental autoimmune uveoretinitis; lovastatin

Indexed keywords

ATORVASTATIN; GAMMA INTERFERON; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; MEVINOLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; INGUINAL LYMPH NODE; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MALE; MICROSCOPY; MORPHOLOGY; MUELLER CELL; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RAT; SUPERNATANT; T LYMPHOCYTE; UVEORETINITIS;

ADMINISTRATION, ORAL; ANIMALS; ARRESTIN; AUTOIMMUNE DISEASES; CATTLE; CELL PROLIFERATION; CYTOKINES; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERSENSITIVITY, DELAYED; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; LOVASTATIN; LYMPH NODES; MACROPHAGES; MODELS, ANIMAL; PYRROLES; RATS; RATS, INBRED LEW; RETINA; RETINITIS; T-LYMPHOCYTES; UVEA; UVEITIS;

EID: 33846799366     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2006.11.011     Document Type: Article

References (31)

1. Black A.E., Sinz M.W., Hayes R.N., and Woolf T.F. Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 26 (1998) 755-763
2. Black A.E., Hayes R.N., Roth B.D., Woo P., and Woolf T.F. Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab. Dispos. 27 (1999) 916-923
3. Butler T.L., and McMenamin P.G. Resident and infiltrating immune cells in the uveal tract in the early and late stages of experimental autoimmune uveoretinitis. Investig. Ophthalmol. Vis. Sci. 37 (1996) 2195-2210
4. Caspi R.R. Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int. Rev. Immunol. 21 (2002) 197-208
5. Cilla D.D., and Whitfield L.R. Multiple-dose pharmacokinetics, pharmacodynamics, and safety and atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin. Pharmacol. Ther. 60 (1996) 687-695
6. Cutts J.L., Scallen T.J., Watson J., and Bankhurst A.D. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J. Cell. Physiol. 139 (1989) 550-557
7. Donoso L.A., Merryman C.F., Shinohara T., Dietzschold B., Wistow G., Craft C., Morley W., and Henry R.T. S-antigen: identification of the MAbA9-C6 monoclonal antibody binding site and the uveitopathogenic sites. Curr. Eye Res. 5 (1986) 995-1004
8. Forrester J.V., Huitinga I., Lumsden L., and Dijkstra C.D. Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats. Curr. Eye Res. 17 (1998) 426-437
9. Gegg M.E., Harry R., Hankey D., Zambarakji H., Pryce G., Baker D., Adamson P., Calder V., and Greenwood J. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J. Immunol. 174 (2005) 2327-2335
10. Inoki T., Yamagami S., Sakai R., Isobe M., Tsuru T., and Kawashima H. Suppression of experimental autoimmune uveoretinitis by anti-alphabeta TCR monoclonal antibody. Jpn. J. Ophthalmol. 46 (2002) 518-524
11. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
12. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M., Chia D., Terasaki P.I., Sabad A., and Cogert G.A. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333 (1995) 621-627
13. Kohno H., Sakai T., and Kitahara K. Induction of nestin, Ki-67, and cyclin D1 expression in Muller cells after laser injury in adult rat retina. Graefe's Arch. Clin. Exp. Ophthalmol. 244 (2006) 90-95
14. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6 (2000) 1399-1402
15. Luna J.D., Chan C.C., Derevjanik N.L., Mahlow J., Chiu C., Peng B., Tobe T., Campochiaro P.A., and Vinores S.A. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J. Neurosci. Res. 49 (1997) 268-280
16. Lacomba M.S., Martin C.M., Chamond R.R., Galera J.M., Omar M., and Estevez E.C. Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Arch. Ophthalmol. 118 6 (2000 Jun) 768-772
17. Mizuguchi J., Takeuchi M., and Usui M. Type I interferons as immunoregulatory molecules; implications for therapy in experimental autoimmune uveoretinitis. Arch. Immunol. Ther. Exp. 50 (2002) 243-254
18. Neuhaus O., Stuve O., Zamvil S.S., and Hartung H.P. Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles. CNS Drugs 19 (2005) 833-841
19. Nicholls S.J., Tuzcu E.M., Schoenhagen P., Sipahi I., Crowe T., Kapadia S., and Nissen S.E. Effect of Atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL Study). Am. J. Cardiol. 96 (2005) 1636-1639
20. Ooi K.G., Galatowicz G., Towler H.M., Lightman S.L., and Calder V.L. Multiplex cytokine detection versus ELISA for aqueous humor: IL-5, IL-10, and IFNgamma profiles in uveitis. Investig. Ophthalmol. Vis. Sci. 47 (2006) 272-277
21. Pahan K., Sheikh F.G., Namboodiri A.M., and Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Investig. 100 (1997) 2671-2679
22. Pouvreau I., Zech J.C., Thillaye-Goldenberg B., Naud M.C., Van Rooijen N., and de Kozak Y. Effect of macrophage depletion by liposomes containing dichloromethylene-diphosphonate on endotoxin-induced uveitis. J. Neuroimmunol. 86 (1998) 171-181
23. Roberge F.G., Caspi R.R., and Nussenblatt R.B. Glial retinal Muller cells produce IL-1 activity and have a dual effect on autoimmune T helper lymphocytes. Antigen presentation manifested after removal of suppressive activity. J. Immunol. 140 (1988) 2193-2196
24. Robertson M.J., Erwig L.P., Liversidge J., Forrester J.V., Rees A.J., and Dick A.D. Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis. Investig. Ophthalmol. Vis. Sci. 43 (2002) 2250-2257
25. Sakai T., Kohno H., Ishihara T., Higaki M., Saito S., Matsushima M., Mizushima Y., and Kitahara K. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp. Eye Res. 82 (2006) 657-663
26. Stanislaus R., Pahan K., Singh A.K., and Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. 269 (1999) 71-74
27. Stanislaus R., Singh A.K., and Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci. Res. 66 (2001) 155-162
28. Thomas P.B., Albini T., Giri R.K., See R.F., Evans M., and Rao N.A. The effects of atorvastatin in experimental autoimmune uveitis. Br. J. Ophthalmol. 89 (2005) 275-279
29. Verwaerde C., Naud M.C., Delanoye A., Wood M., Thillaye-Goldenberg B., Auriault C., and de Kozak Y. Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Gene Ther. 10 (2003) 1970-1981
30. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., and Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7 (2001) 687-692
31. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., and Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84